Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
boston blog main
boston top stories
deals
5
×
life sciences
national blog main
clinical trials
national top stories
san francisco blog main
boston
san francisco top stories
cancer drugs
fda
investing
new york blog main
new york top stories
roche
abbvie
acute myeloid leukemia
alexion pharmaceuticals
allergan
alnylam pharmaceuticals
alx oncology
alzheimer's disease
amgen
autoimmune diseases
azacitidine
berkeley lights
beta-thalassemia
biotech ipos
boehringer ingelheim
cancer
cancer immunotherapy
cd47
chronic kidney disease
cobimetinib
crispr
cynthia collins
dacogen
decitabine
What
research
5
×
medicines
biotech
drug
gene
ipo
new
abbvie
aims
alliance
approach
arrival
based
called
cancer
caught
causing
companies
days
debuts
despite
developing
dicerna
disease
drugs
editas
editing
epigenetic
epigenetics
exits
experimental
eye
family
field
flagship’s
genetic
hardest
hasn’t
hepatitis
hit
Language
unset
Current search:
biotech
×
deals
×
research
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further